Dexmedetomidine + Midazolam
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Continuous Sedation in Initially Sedated Adults in ICU
Conditions
Continuous Sedation in Initially Sedated Adults in ICU
Trial Timeline
Jun 1, 2007 → Oct 1, 2009
NCT ID
NCT00481312About Dexmedetomidine + Midazolam
Dexmedetomidine + Midazolam is a phase 3 stage product being developed by Orion Corporation for Continuous Sedation in Initially Sedated Adults in ICU. The current trial status is completed. This product is registered under clinical trial identifier NCT00481312. Target conditions include Continuous Sedation in Initially Sedated Adults in ICU.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00481312 | Phase 3 | Completed |
Competing Products
2 competing products in Continuous Sedation in Initially Sedated Adults in ICU
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ertapenem | Merck | Approved | 85 |
| Dexmedetomidine + Propofol | Orion Corporation | Phase 3 | 74 |